

CSU IBC Meeting Approved Minutes

Meeting title	CSU IBC Meeting November 2025
Date	November 12, 2025
Convened at	12:00pm MST
Location	Microsoft Teams (Virtual Meeting)
Open or closed meeting (If closed, why?)	The Meeting was open for the entirety of the meeting.
Review of prior meeting minutes	October 15, 2025 minutes were approved as written.
Adjournment	12:32pm MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
<input checked="" type="checkbox"/> Jessica Ayers, Animal expert	<input type="checkbox"/> Lon Kendall, Director LAR
<input type="checkbox"/> Donald Bade, Unaffiliated	
<input checked="" type="checkbox"/> Angela Bosco-Lauth, Veterinary Virology	
<input checked="" type="checkbox"/> Chaoping Chen, Chair	
<input checked="" type="checkbox"/> Jason Cummings, lab representative	
<input checked="" type="checkbox"/> Dan Frazen, Unaffiliated	
<input checked="" type="checkbox"/> Brendan Podell, Mycobacteria specialist	
<input type="checkbox"/> Ann Powers, Virology	
<input checked="" type="checkbox"/> Robyn Roberts, Plant expert	
<input checked="" type="checkbox"/> Joanie Ryan, Assistant Biosafety Director*	<input checked="" type="checkbox"/> Rebecca Moritz, Biosafety Office Director
<input checked="" type="checkbox"/> Tony Schountz, Virology	<input checked="" type="checkbox"/> Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 6 voting members; 9 in attendance	*non-voting at this meeting
Non-Voting Members:	
<input type="checkbox"/>	
<input checked="" type="checkbox"/> Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
<input checked="" type="checkbox"/> Michelle Ramey, Assistant Compliance Coord.	<input checked="" type="checkbox"/> Sonia Aleman Rivera, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Nicole Marlenee, Biosecurity Specialist	<input checked="" type="checkbox"/> Kelly Kim, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC; Jim Abraham, Interim EHS Director; 2 members of the public were present	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Review of October 15, 2025, IBC meeting minutes

The minutes were unanimously approved as written.

2. Agent/Project Review

a. PI name/Lab	Goodrich Lab
Project Number and Title	25-072B: Production and use of multivalent immunoglobulin Y antibodies as a prophylactic and therapeutic tool
Agents used	<ul style="list-style-type: none"> • Burkholderia thailandensis • Pseudomonas aeruginosa
Project Overview	The proposed research aims to develop a therapeutic approach based on Immunoglobulin Y (IgY) to treat enteric pathogens (pathogens in the intestines of animals and humans) and counter the emerging threat of antibiotic resistance. IgY preparations will be tested in vitro against fully virulent isolates of V. cholera, Shigella, Pseudomonas aeruginosa, Burkholderia thailandensis and/or E. coli during in vitro infection of human epithelial cell cultures.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL1
Discussion	<p>This is an established PI/Lab: Under Description of Experimental and Procedural Details, the IBC requested more detail regarding the inactivation process</p> <p>For Burkholderia thailandensis</p> <ol style="list-style-type: none"> 1. A surgical mask is typically not required for work with this agent. Please elaborate on why it is included as required PPE 2. Will an autoclave be used for waste? 3. Will MicroChem Plus be used as it is described for the other agents? 4. The bleach concentration must at least 10%, please adjust the dilution calculation appropriately. 5. Is the agent arriving freeze-dried? Will sharps be required to reconstitute the agent? If yes, this information should be added. <p>For Pseudomonas aeruginosa</p> <p>Under Step IV, please provide more agent-specific information in the Risk Assessment - for example what are the symptoms associated with infection, primary route of exposure, and risks of exposure in the laboratory.</p>
Verification of training	A few lab personnel have training due to complete.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

3. Amendments requiring full IBC review

a. PI name/Lab	Woerman Lab
Project Number and Title	23-039B: Investigating prion strain biology
Agents used (toxin)	alpha-synuclein prions, human tau prions, adeno-associated virus
Project Overview	In healthy individuals, the proteins tau and alpha-synuclein misfold into prions that then spread throughout the brain giving rise to neurodegenerative diseases. This laboratory investigates the mechanisms by which this process occurs, how the proteins misfold into different shapes (or strains) to cause unique neurodegenerative disorders, the pathogenesis of each prion strain, and tools for diagnosing and treating patients with these disorders.
Amendment request	They are looking to expand their work developing gene therapies, which includes increasing the number of AAV capsids they are testing for maximizing therapeutic development.
Planned Modifications	The new AAV capsids will be tested in mice to deliver the GFP gene to determine which capsid/injection route combination achieves greatest distribution, which will then be used for gene therapy development.
NIH Guidelines Section	III-D-2, III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	This is an established lab: The IBC requests clarification regarding whether the intent is to increase the viral number or the number of AAV capsids.
Verification of training	All lab personnel training is current.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the amendment request with modifications described above (see Discussion)
Vote	The motion was unanimously approved.

4. New Business

a. Updated Policy on Noncompliance Involving Biohazardous Materials

The noncompliance policy was updated with the intent to streamline the document and the process, and the draft was sent to the committee for review. Items discussed included, defining “significant” change in protocol, the timeline for the noncompliance review process, and whether a PI could have their lab access revoked. Recommended changes included, defining “significant” change in protocol more clearly, and updating the line under corrective actions to indicate protocol submission/amendment prior to work continuing. The policy was unanimously approved with the minor changes mentioned.

5. Unfinished Business

a. McKay Lab – TABLED from September meeting, awaiting response

i. Pathogen Registration Forms

1. Bacteria - *Xanthomonas vasicola vasculorum*

ii. **Project - Identification of Durable Disease Tolerance Gene(s) under Drought Stress in Maize (25-059B); BSL1/BSL1-P. NIH Guidelines category non-exempt rDNA: NA**

6. Reports

<p>a. Coordinator’s Report</p>	<p>1. IBC membership update Dr. Peccoud stepped down due to moving to position in Europe, thus we are working to recruit a new member. Dr. Peccoud made a few suggestions, and we welcome suggestions from the committee. The roster with NIH has not been updated yet because portal is down due to the government shutdown.</p> <p>2. Next IBC meeting: Wednesday, December 10, 2025</p>
<p>b. Biosafety Office Report</p>	<p>1. Inspections update: lab visits are going well; no federal updates because of the shut down</p> <p>2. Incident Reports: no incidents to report</p>

7. Public Comment

No comments were made.

8. Items to be read into the minutes

<p>a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed</p>	<p>1. Braunstein Lab Project: <u>Transposon mutagenesis in the NTM <i>Mycobacterium abscessus</i> (25-063B); BSL2. NIH Guidelines category non-exempt rDNA: NA</u></p> <p>2. Sloan, Daniel – Amendment Project: <u>Modification of <i>Arabidopsis</i> organelle DNA polymerase fidelity (20-124B); BSL1/BSL-P, rDNA. NIH Guidelines category non-exempt rDNA: III-E-2</u></p>
<p>3. Items Reviewed and Approved by the Biosafety Officer or Chair since the last meeting</p>	<p>1. Bell Lab Project: <u>Influence of Short-Term Antibiotic Therapy on Exercise (25-067B); BSL2, human samples. NIH Guidelines category non-exempt rDNA: NA</u></p> <p>2. Bowen Lab Project: <u>Testing Reactogenicity of a <i>Coxiella</i> vaccine (25-068B); BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA</u></p> <p>3. BioMARC (Heaslip) Lab Project: <u>Small scale screening of SARS-CoV-2 Omicron Variants (25-070B); BSL2. NIH Guidelines category non-exempt rDNA: NA</u></p>

	<p>4. Robertson Lab</p> <p>Project: <u>TB discovery in vivo support for long-acting injectables</u> (25-065B); BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA</p> <p>Project: <u>next gen rifamycins in a mouse model of necrotic lesions</u> (25-066B); BSL3/ABSL3. NIH Guidelines category non-exempt rDNA: NA</p>
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------